Corient IA LLC Invests $273,000 in DexCom, Inc. $DXCM

Key Points

• Corient IA LLC has acquired 4,000 shares of DexCom, Inc. valued at approximately $273,000, marking a new stake according to their SEC filing.
• Institutional investors own about 97.75% of DexCom's stock, with Vanguard Group increasing its holdings by 2.0% in the first quarter.
• Analysts have given DexCom's stock an average rating of "Moderate Buy" with a target price of $99.89, indicating a positive outlook.

Corient IA LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,000 shares of the medical device company's stock, valued at approximately $273,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Horizon Investments LLC increased its holdings in DexCom by 2.2% in the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after buying an additional 123 shares in the last quarter. Nia Impact Advisors LLC lifted its position in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after buying an additional 140 shares in the last quarter. Wedbush Securities Inc. lifted its position in shares of DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock valued at $899,000 after buying an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. lifted its holdings in DexCom by 3.2% in the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after purchasing an additional 182 shares in the last quarter. Finally, Trivium Point Advisory LLC lifted its holdings in DexCom by 6.1% in the 1st quarter. Trivium Point Advisory LLC now owns 3,455 shares of the medical device company's stock worth $236,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the transaction, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $88.99, for a total value of $130,459.34. Following the completion of the transaction, the executive vice president owned 106,689 shares of the company's stock, valued at approximately $9,494,254.11. The trade was a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,906 shares of company stock valued at $1,832,451. 0.32% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DXCM. Robert W. Baird reduced their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Canaccord Genuity Group reissued a "buy" rating and set a $106.00 target price on shares of DexCom in a research report on Friday, August 1st. Oppenheimer upped their price objective on DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Mizuho upped their price objective on DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Finally, Argus started coverage on DexCom in a report on Thursday. They issued a "buy" rating and a $100.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $99.90.

DexCom Stock Up 2.0%

DexCom stock traded up $1.64 during midday trading on Friday, reaching $82.26. The company's stock had a trading volume of 2,403,453 shares, compared to its average volume of 3,863,906. The stock's 50-day simple moving average is $82.81 and its 200-day simple moving average is $79.93. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The stock has a market capitalization of $32.26 billion, a P/E ratio of 57.13, a PEG ratio of 1.71 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period last year, the business posted $0.43 earnings per share. The firm's revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.